BioSpace News Archive

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced results from a landmark study investigating how different breast implant surfaces affect the host immune response.

The market is estimated to grow with a CAGR of 9.5% from 2019-2027.

The report highlights the trends prevailing in the market, along with market drivers and deterrents.

The COVID-19 pandemic has affected individuals, families, and communities in many ways. , on National Indigenous Peoples Day, it is important that we acknowledge the inequitable impacts that the COVID-19 pandemic has had on Indigenous peoples across the country.

AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR-T cells against solid cancers, announced today the addition of Matt Britz to its management team as its Senior Vice President of Business Development.

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its fourth quarter fiscal year 2021, ended March 31, 2021, at 4:15 p.m. ET on Thursday, June 24, 2021

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the closing of an underwritten public offering of 4,887,500 shares of its common stock.

Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the LifeSci Partners Genetic Medicines Summit

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Elaine Caughey, MBA, as Chief Business Officer.

Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced initiation of a potential registration-enabling Phase 2 study of INBRX-109 in conventional chondrosarcoma.